Themis Medicare Limited (IN:THEMISMED)
:THEMISMED
Want to see IN:THEMISMED full AI Analyst Report?
THEMISMED Stock Chart & Stats
₹102.50
₹17.25(6.68%)
At close: 4:00 PM EST
₹102.50
₹17.25(6.68%)
Day’s Range― - ―
52-Week Range₹65.00 - ₹147.99
Previous CloseN/A
Volume256.77K
Average Volume (3M)6.87K
Market Cap
₹9.23B
Enterprise Value₹11.00B
Total Cash (Recent Filing)₹189.59M
Total Debt (Recent Filing)₹955.64M
Price to Earnings (P/E)841.4
Beta1.56
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.48%
Share Statistics
EPS (TTM)-2.92
Shares Outstanding92,100,120
10 Day Avg. Volume6,301
30 Day Avg. Volume6,868
Financial Highlights & Ratios
PEG Ratio-5.72
Price to Book (P/B)1.58
Price to Sales (P/S)1.84
P/FCF Ratio-37.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageLow debt relative to equity gives the company financial flexibility to withstand continued margin pressure and fund working capital or strategic investments without heavy interest burden. This balance sheet cushion supports durability while management works to restore profitability.
Diversified Product And Market MixHaving both APIs and finished formulations and exposure to domestic and export markets provides structural revenue diversification. This mix reduces single-market dependency, enables margin optimization via product mix shifts, and supports resilience across regulatory and demand cycles.
Recent Revenue ReboundA material top-line recovery indicates regained demand or better execution and can enable scale benefits if sustained. Higher volumes can improve fixed-cost absorption and support long-term margin recovery if management controls costs and rebalances product mix toward higher-margin lines.
Bears Say
Sharp Margin DeteriorationA large, rapid collapse in gross margin signals structural pressure from pricing, cost inflation, or an adverse product mix. Sustained lower gross margins erode operating leverage, make profitability recovery harder, and reduce the firm's ability to self-fund investments or absorb shocks.
Negative Operating And Free Cash FlowPersistent negative OCF and FCF materially weakens internal funding capacity, increasing reliance on external financing or equity. Over months this constrains working-capital management, capex, and R&D, raising liquidity and execution risk if cash generation does not normalize.
Collapsed Returns On EquityA steep drop in ROE shows the company is currently not translating equity into meaningful earnings. This reflects weak profitability and lowers long-term shareholder value creation, making it harder to attract capital and necessitating strategic changes to restore returns.
Themis Medicare Limited News
THEMISMED FAQ
What was Themis Medicare Limited’s price range in the past 12 months?
Themis Medicare Limited lowest stock price was ₹65.00 and its highest was ₹147.99 in the past 12 months.
What is Themis Medicare Limited’s market cap?
Themis Medicare Limited’s market cap is ₹9.23B.
When is Themis Medicare Limited’s upcoming earnings report date?
Themis Medicare Limited’s upcoming earnings report date is Aug 07, 2026 which is in 54 days.
How were Themis Medicare Limited’s earnings last quarter?
Themis Medicare Limited released its earnings results on May 28, 2026. The company reported ₹0.96 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.96.
Is Themis Medicare Limited overvalued?
According to Wall Street analysts Themis Medicare Limited’s price is currently Overvalued.
Does Themis Medicare Limited pay dividends?
Themis Medicare Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.48%. See more information on Themis Medicare Limited dividends here
What is Themis Medicare Limited’s EPS estimate?
Themis Medicare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Themis Medicare Limited have?
Themis Medicare Limited has 92,100,120 shares outstanding.
What happened to Themis Medicare Limited’s price movement after its last earnings report?
Themis Medicare Limited reported an EPS of ₹0.96 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Themis Medicare Limited?
Currently, no hedge funds are holding shares in IN:THEMISMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Themis Medicare Limited
Themis Medicare Limited, along with its affiliated entities, is a pharmaceutical company that produces and supplies medicinal goods for both the Indian and international markets. Its product portfolio encompasses active pharmaceutical ingredients (APIs) and various drug formulations, designed for application across diverse medical domains such as anti-infectious conditions, malaria, tuberculosis, cardiovascular issues, health and wellness, cancer, eye diseases, and pain relief. Founded in 1969, the company operated under the name Themis Chemicals until 2001, when it officially changed to Themis Medicare Limited. The company's primary operations are directed from its Mumbai, India headquarters.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Jagsonpal Pharmaceuticals Ltd.
―
Venus Remedies Limited
―
Wanbury Limited
―
Zim Laboratories Ltd.
―